Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Our mission is to become the world leader in developing better and safer antibody-based oncology products addressing clear unmet pediatric and adult medical needs. With the right partnerships and collaborations, we envision changing the course of cancer care and its outcomes.
我們正在追蹤 Y-mAbs Therapeutics, Inc. 的市場擴張
過去 90 日內有 6 個訊號。
Y-mAbs Therapeutics, Inc. 的國際擴張與競爭對手的比較
Y-mAbs Therapeutics, Inc.你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Y-mAbs Therapeutics, Inc.你 | 0 | 0 | — | 0 | 0 |
Senior Director / Director, Medical (Oncology)
查看招聘Copenhagen, Capital Region of Denmark, Denmark · 11個月前
Senior Manager / Associate Director, GMP Global QA
查看招聘Hørsholm, Capital Region of Denmark, Denmark · 11個月前
Finance Manager
查看招聘Hørsholm, Capital Region of Denmark, Denmark · 上年
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
Telix Pharmaceuticals任命David Gill為非執行董事,於2026年5月11日生效,計劃讓他擔任主席。Gill擁有超過35年生命科學經驗。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Y-mAbs Therapeutics, Inc. 業務、市場及增長訊號的快速解答。
